Imagine a smart cap that gently squeezes the scalp to act like a temporary dam. This prevents chemotherapy drugs from reaching the hair follicles, which are the parts that cause hair to fall out. Instead of using freezing cold caps, it uses a soft robotic system to keep the hair safe while the medicine works elsewhere in the body.
Cancer patients face severe psychological trauma from hair loss, and current solutions are either ineffective cover-ups or painful, expensive, and unregulated cryogenic caps.
A portable wearable device featuring a pneumatic bladder network, a soft robotics system for scalp compression, and an electronic control system for real-time feedback.
If you are a hardware developer dealing with the lack of regulated CIA prevention tools — this project developed a portable pneumatic bladder system that provides a comfortable alternative to cold caps. It uses a pressure range of 35 to 60 mmHg to inhibit drug delivery to follicles.
If you are a clinic dealing with patients who find cryogenic equipment too expensive or painful — this project developed a wearable, patient-controlled device. This allows clinics to offer a more dignified and accessible hair-loss prevention option without heavy capital investment.
If you are a software provider dealing with a lack of real-time feedback in oncology support — this project developed an electronic control system for patient management. It integrates real-time feedback into the treatment protocol for better quality of life.
Based on available project data, the specific unit price is not mentioned, but it is noted that current cryogenic equipment requires significant capital investment, which LILY aims to avoid.
The device uses a proprietary pneumatic bladder network and soft robotics, which are components suitable for medical device manufacturing. Based on available project data, it is designed as a portable, wearable solution for wide accessibility.
The project mentions a proprietary pneumatic bladder network design. Based on available project data, specific licensing terms are not disclosed.
The project highlights that current alternatives like cold caps are not FDA regulated or CE Mark approved, positioning LILY as a professional medical device development.
The project period runs from 2023-10-01 to 2026-03-31.
The project is led by a single SME, Luminate Medical Limited from Ireland. With a 100% industry ratio and a total EU contribution of EUR 2,499,999, the project is lean and focused on commercialization rather than academic research, which typically accelerates the path to market.
Contact Luminate Medical Limited in Ireland
Contact us to explore licensing opportunities for LMCT technology.
